检索结果-南通市图书馆

One p.tient with metastastic color.ctal cancer successfully tr.ated by combination of tar.eted agents after.failur. of chemother.0}y

引用

Chinese Jour.al of cancer 2010年第12期29卷 1023-1028页

作者： Liang-p.ng Xia1,2, p.i-Hong Wu1,3, Jian-Chuan Xia1,4, Bei Zhang1,2, Zhong-Zhen Guan1,5, De-sen Wan1,6, Gui-Fang Guo1,2, Yi-Xin Zeng1,7 1 State Key Labor.tor. of oncology in South china, guangzhou, guangdong 510060, p. r. china 2 VIp.r.gion, sun yat-sen univer.ty cancer center, guangzhou, guangdong 510060, p. r. china 3 department of medical Imaging and Inter.entional r.diology, sun yat-sen univer.ty cancer center, guangzhou, guangdong 510060, p. r. china 4 Biother.p. cancer, sun yat-sen univer.ty cancer center, guangzhou, guangdong 510060, p. r. china 5 department of medical oncology, sun yat-sen univer.ty cancer center, guangzhou, guangdong 510060, p. r. china 6 department of Color.ctal cancer,sun yat-sen univer.ty cancer center, guangzhou, guangdong 510060, p. r. china 7 sun yat-sen univer.ty cancer center, guangzhou, guangdong 510060, p. r. china VIp.r.gion Sun Yat-sen Universty Cancer Center StateKey Laboratory of Oncology in South China Guangdong Guangzhou 510060 department of medical Imaging and Inter.entional r.diology Sun Yat-sen Universty Cancer Center StateKey Laboratory of Oncology in South China Guangdong Guangzhou 510060 Biother.p. cancer Sun Yat-sen Universty Cancer Center StateKey Laboratory of Oncology in South China Guangdong Guangzhou 510060 department of medical oncology Sun Yat-sen Universty Cancer Center StateKey Laboratory of Oncology in South China Guangdong Guangzhou 510060 department of Color.ctal cancer Sun Yat-sen Universty Cancer Center StateKey Laboratory of Oncology in South China Guangdong Guangzhou 510060 sun yat-sen univer.ty cancer center StateKey Laboratory of Oncology in South China Guangdong Guangzhou 510060

Either.cetuximab or.bevacizumab can imp.ove the sur.ival of p.tients with metastastic color.ctal cancer (mCr.) if administer.d combided with cytotoxic agents. However. the effect of two or.mor. tar.et agents in combination is uncer.ain in these p.tients. Her., we r.p.r.ed a p.tient with mCr. successfully tr.ated by a combination of tar.et agents after.the failur. of chemother.p.. The p.tient r.ceived p.lliative r.section of p.imar. tumor.followed by 9 cycles of p.stop.r.tive XELOX r.gimen, cytokine-induced killer.cell (CIK)-based biother.p., tr.ditional Chinese medicine, p.r.icle imp.antation in the lung metastatic lesions. The tumor.p.ogr.ssed 20 months after.the standar. tr.atments. Then, the r.gimen cetuximab, bevacizumab and cefitinib was ap.lied. Dur.ng the tr.atment with tar.eted agents, gr.de IV acne-like r.sh and r.latively sever. p.r.onychia of the toes occur.ed. Both of them r.cover.d smoothly. The p.T-CT r.examination at 40 days after.the tar.et tr.atment showed that the metabolism of mediastinal lymp. nodes basically r.cover.d to a nor.al level. The combination of multip.e tar.eted agents obtained a p.ogr.ssion-fr.e sur.ival(p.S) of 11 months and the p.tient with a good quality of life dur.ng this p.r.od.

关键词：药物治疗结直肠癌转移性患者大肠细胞毒性靶向药物不确定性

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Antiangiogenic ther.p.:a novel ap.r.ach to over.ome tumor.hyp.xia

引用

Chinese Jour.al of cancer 2010年第8期29卷 715-720页

作者： Fang p.ng1,2, Ming Chen1,2 1 State Key Labor.tor. of oncology in South china, guangzhou, guangdong 510060, p. r. china 2 department of r.diation oncology, sun yat-sen university cancer center, guangzhou, guangdong 510060, p. r. china department of r.diation oncology Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China Guangdong Guangzhou 510060

Hyp.xia is a common p.enomenon in solid tumor.. r.sistance of hyp.xic tumor.cells to r.diation is a significant r.ason of failur. in the local contr.l of tumor.. The gr.wth and metastasis of solid tumor. r.ly on blood vessels. Antiangiogenic agents mainly tar.et tumor.blood vessels, and r.diation ther.p. mainly tar.ets tumor.cells. Combination of antiangiogenic tr.atment and r.diation exhibits syner.istic effect, which imp.oves the r.sp.nse of tumor. to r.diation ther.p.. The mechanisms of inter.ction between antiangiogenic agents and ionizing r.diation ar. comp.ex and involve inter.ctions between tumor.cells and tumor.micr.envir.nment, including tumor.oxygenation, str.ma, and vasculatur.. The or.ginal mechanism of antiangiogenesis is to induce ischemia and hyp.xia in tumor., ther.by, "star.e" the tumor.. However. r.cently, emer.ing data suggest that antiangiogenic agents could r.duce the p.op.r.ion of hyp.xic cells thr.ugh nor.alizing tumor.vasculatur., decr.asing oxygen consump.ion, and other.mechanisms. The use of antiangiogenic agents p.ovides a new ap.r.ach to over.ome the hyp.xia p.oblem, and ultimately imp.oves the efficacy of r.diation ther.p.. In this r.view, we discuss tumor.hyp.xia, tumor.angiogenesis and its r.gulation, mechanisms of antiangiogenic ther.p. combined with r.diation ther.p., and how antiangiogenic ther.p. over.omes tumor.hyp.xia.

关键词：抗血管生成肿瘤细胞抗缺氧疗法放射治疗电离辐射肿瘤血管生成相互作用

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Exp.ession of hep.titis B vir.s sur.ace antigen in 120 Hodgkin's lymp.oma p.tients

引用

Chinese Jour.al of cancer 2010年第8期29卷 735-740页

作者： Miao-Zhen Qiu1,2, Dan-Yun r.an1,2, Zhi-Qiang Wang1,2, Hui-Yan Luo1,2, Kai-Yuan Teng1,2, Zhong-Jun Xia1,3, Yue Lu1,3, Hui-Qiang Huang1,2, Wen-Qi Jiang1,2, r.i-Hua Xu1,2 1 State Key Labor.tor. of oncology in South china, sun yat-sen university cancer center, guangzhou, guangdong 510060, p. r. china 2 department of medical oncology, sun yat-sen university cancer center, guangzhou, guangdong 510060, p. r. china 3 department of Hematology oncology, sun yat-sen university cancer center, guangzhou, guangdong 510060, p. r. china sun yat-sen university cancer center State Key Laboratory of Oncology in South China Guangdong Guangzhou 510060

Backgr.und and Objective: Little is known about the incidence of hep.titis B vir.s (HBV) infection in Hodgkin's lymp.oma p.tients. This study was to evaluate the imp.ct of HBV infection on the sur.ival of Hodgkin's lymp.oma p.tient. Methods: Clinical data of 120 Hodgkin's lymp.oma p.tients tr.ated at the sun yat-sen university cancer center between Januar. 2004 and October.2007 wer. collected. The imp.ct of p.ognostic factor. including HBV infection on sur.ival was examined by univar.ate and multivar.ate analyses. A log-r.nk test was used for.univar.ate analysis and the Cox p.op.r.ional hazar.s r.gr.ssion model was used for.multivar.ate analysis. r.sults: Of the 120 p.tients, 18 (15.0%) wer. hep.titis B vir.s sur.ace antigen (HBsAg)-p.sitive. The HBsAg-p.sitive p.tients had lower.5-year.sur.ival r.te than did the HBsAg-negative ones (66.9% vs. 91.3%, p.= 0.006). When the p.tients wer. divided into ear.y-stage (Ⅰ+Ⅱ) and advanced-stage (Ⅲ+Ⅳ) gr.up., the 5-year.sur.ival r.te was significantly differ.nt between the HBsAg-p.sitive and -negative p.tients in ear.y-stage gr.up.(64.8% vs. 96.0%, p.r.nt in advanced-stage gr.up.(75.0% vs. 84.8%, p.0.667). Both univar.ate and multivar.ate analyses showed that r.diother.p. and HBV infection wer. indep.ndent p.ognosis factor. for.the p.tients with ear.y-stage Hodgkin's lymp.oma (p.0.006 and 0.014, r.sp.ctively). Conclusions: The incidence of HBV infection is similar.between Hodgkin's lymp.oma p.tients and nor.al p.p.lation. HBV infection is an indep.ndent p.ognosis factor.for.sur.ival in the p.tients with ear.y-stage Hodgkin's lymp.oma.

关键词：乙肝病毒表面抗原淋巴瘤患者乙肝表面抗原多因素分析金病毒感染肝炎病毒

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Cor.elation analysis between loss of heter.zygosity at chr.mosome 18q and p.ognosis in the stage-Ⅱ colon cancer p.tients

引用

Chinese Jour.al of cancer 2010年第8期29卷 761-767页

作者： Wei Wang1,2, Yuan-Fang Li1,2, Xiao-Wei sun1,2, Gong Chen1,3, You-Qing Zhan1,2, Chun-Yu Huang1,2, De-sen Wan1,3, Zhi-Zhong p.n1,3, Zhi-Wei Zhou1,2 1 State Key Labor.ar. of oncology in South china, guangzhou, guangdong 510060, p. r. china 2 department of Gasr.ic and p.ncr.atic Sur.er., sun yat-sen university cancer center, guangzhou, guangdong 510060, p. r. china 3 department of Color.ctal Sur.er., sun yat-sen university cancer center, guangzhou, guangdong 510060, p. r. china department of Gasr.ic and p.ncr.atic Sur.er. Sun Yat-sen University Cancer Center State Key Labortary of Oncology in South China Guangdong Guangzhou 510060 department of Color.ctal Sur.er. Sun Yat-sen University Cancer Center State Key Labortary of Oncology in South China Guangdong Guangzhou 510060

Backgr.und and Objective: Color.ctal cancer is one of the most common malignant cancers in the wor.d. Although the clinicop.thologic staging is the golden cr.ter.on for.the p.ognosis at p.esent, the op.imum p.ognostic cr.ter.a for.color.ctal cancer should be a combination of the clinicop.thologic staging and the molecular.mar.er.. However. ther. ar. cur.ently no molecular.mar.er. available for.the p.ognosis of color.ctal cancer. Sever.l tumor.sup.r.ssor.genes associated with color.ctal cancer have been map.ed at the 18q21-23 r.gion. In this study we detected the fr.quency of loss of heter.zygosity (LOH) at chr.mosome 18q and investigated the r.lationship.between LOH and clinicop.thologic featur.s and its p.ognostic value for.p.tients with stage Ⅱ colon cancer. Methods: A total of 106 samp.es of tumor.tissues and cor.esp.nding nor.al mucosa fr.m p.tients with sp.r.dic stage-Ⅱ colon cancer wer. included in this study. All the samp.es wer. for.alin-fixed and p.r.ffin-embedded. DNA was extr.cted fr.m tumor.tissues and LOH of D18S474, D18S55, D18S58, D18S61 and D18S64 at chr.mosome 18q was analyzed using p.lymer.se chain r.action (p.r., p.lyacr.lamide gel-electr.p.or.sis, and DNA sequencing method. Multivar.ate analysis for.association between LOH and p.ognosis in colon cancer p.tients was p.r.or.ed with Cox p.op.r.ional hazar.s r.gr.ssion model. r.sults: The median follow-up.time was 68 months. For.106 p.tients, 5-year.sur.ival r.te was 83.6%, which was associated with age and gr.ss tumor.typ. (p.= 0.011 and 0.034, r.sp.ctively). Among 102 p.tients who wer. eligible for.LOH infor.ation, the over.ll fr.quency of LOH is 49.0% (50/102), and that of LOH at 5 micr.satellite loci of D18S474, D18S55, D18S58, D18S61, and D18S64 was 30.2% (26/86), 23.4% (18/77), 28.6% (20/70), 35.0% (28/80), and 20.8%(15/72), r.sp.ctively. The occur.ence of LOH was significantly associated with tumor.location and histop.thologic gr.de (p.= 0.023, 0.016 and 0.005, r.sp.ctively). LOH was mor. fr.q

关键词：大肠癌染色体杂合性预后患者相关分析聚丙烯酰胺凝胶电泳临床病理

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

p.r.utaneous r.diofr.quency ablation ap.r.ach thr.ugh the sp.een:initial case r.p.r. for.p.ncr.atic tail gastr.noma

引用

Chinese Jour.al of cancer 2010年第9期29卷 836-841页

作者： p.i-Hong Wu1,2, Chang-Chuan p.n1,2, Zi-Lin Huang1,2, Wang Li1,2, Ming Zhao1,2, Zhi-Wei Zhou1,3 1 State Key Labor.tor. of oncology in South china, guangzhou, guangdong 510060, p.r.china 2 department of medical Imaging & Inter.entional r.diology, sun yat-sen university cancer center, guangzhou, guangdong 510060, p.r.china 3 department of Abdominal oncology, sun yat-sen university cancer center, guangzhou, guangdong 510060, p.r.china department of medical Imaging& Inter.entional r.diology Sun Yat-s en University Cancer Center State Key Laboratory of Oncology in South China Guangdong Guangzhou 510060 department of Abdominal oncology Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China Guangdong Guangzhou 510060

Gastr.noma has a low incidence, and the p.ncr.as-or.ginated gastr.noma is *** gastr.noma p.tients with liver.metastases have p.or.p.ognosis and shor. *** tr.atment to r.duce the tumor.bur.en help. to imp.ove symp.oms and slows down tumor.p.ogr.ssion for.p.tients with unr.sectable *** r.p.r. a case of p.ncr.atic tail gastr.noma with unr.sectable liver.*** p.tient r.ceived a comp.ehensive minimally invasive inter.entional tr.atment, that is, chemoembolization and r.diofr.quency ablation for.liver.metastases, and p.r.utaneous tr.nsp.enic r.diofr.quency ablation combined with r.dioactive 125I seed imp.antation for.p.ncr.atic tail *** p.tient was followed up.for.mor. than 20 months, and showed no clear.evidence of tumor.*** exp.or.d the safety and feasibility of p.r.utaneous tr.nsp.enic r.diofr.quency ablation for.unr.sectable p.ncr.atic tail *** tr.nsp.enic ap.r.ach allow mor. indications for.minimally invasive ther.p. and p.ovides a new tr.atment op.ion not only for.p.tients with unr.sectable p.ncr.atic tail tumor.but also for.p.tients r.fusing sur.er..

关键词：射频消融胃泌素病例报告尾部局部治疗手术切除肿瘤病介入治疗

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Imp.ct of Kr.S mutation and p.EN exp.ession on cetuximab-tr.ated color.ctal cancer

引用

Wor.d Jour.al of Gastr.enter.logy 2010年第46期16卷 5881-5888页

作者： Fang-Hua Li,Zhuang-Hua Li,Hui-Yan Luo,Miao-Zhen Qiu,Yu-Hong Li,r.i-Hua Xu,State Key Labor.tor. of oncology in Souther. china,department of medical oncology,sun yatsen university cancer center,guangzhou 510060,guangdong p.ovince,china Fang-Hua Li,department of medical oncology,Shengli Oil Field Centr.l Hosp.tal,Dongying 257034,Shandong p.ovince,china Lin Shen,department of GI oncology,p.king university School of oncology,Beijing cancer Hosp.tal and Institute,Beijing 100142,china Hui-Zhong Zhang,State Key Labor.tor. of oncology in Souther. china,department of p.thology,sun yat-sen university cancer center,guangzhou 510060,guangdong p.ovince,china State Key Labor.tor. of oncology in Souther. china Department of Medical Oncology Sun Yat-Sen University Cancer Center Guangzhou 510060 Guangdong Province China.

AIM:To investigate the p.ognostic value of Kr.S mutation,and p.osp.atase and tensin (p.EN) exp.ession in Chinese metastatic color.ctal cancer metastatic color.ctal cancer (mCr.) p.tients tr.ated with ***:Ninety Chinese mCr. p.tients tr.ated with cetuximab wer. evaluated for.Kr.S mutation and p.EN p.otein exp.ession by DNA sequencing of codons 12 and 13 and immunohistochemistr.,*** then selected 61 p.tients tr.ated with cetuximab,either.in combination with chemother.p.,or.alone as a second-line or.thir.-line r.gimen to assess whether.Kr.S mutation or.p.EN p.otein exp.ession is associated with the r.sp.nse and the sur.ival time of mCr. p.tients tr.ated with ***:Kr.S mutation was found in 30 (33.3%) tumor.samp.es fr.m the 90 p.tients,and p.sitive p.EN exp.ession was detected in 58 (64.4%) of the 90 *** the 61 p.tients who wer. tr.ated with cetuximab as a second-line or.thir.-line r.gimen,the r.sistance to cetuximab was found in 22 p.tients with Kr.S mutation and in 39 p.tients without Kr.S mutation,with a r.sp.nse r.te of 4.5% and 46.1% r.sp.ctively (p.0.001),a shor.er.median p.ogr.ssion-fr.e sur.ival (p.S) time of 14 ± 1.3 wk and 32 ± 2.5 wk r.sp.ctively (p.r.ll sur.ival (OS) time of 11 ± 1.2 mo and 19 ± 1.8 mo r.sp.ctively (p.p.tients with negative p.EN exp.ession and in 37 p.tients with p.sitive p.EN exp.ession r.sp.ctively (p.r.sp.nsive r.te of 4.2% and 48.6% r.sp.ctively,a shor.er.median p.S sur.ival time of 17 ± 2.0 wk and 28 ± 1.9 wk r.sp.ctively (p.0.07),and a median OS time of 11 ± 1.3 mo and 18 ± 1.9 mo r.sp.ctively (p.0.004).Combined Kr.S mutation and p.EN exp.ession analysis showed that the p.S and OS time of p.tients with two favor.ble p.ognostic factor. wer. longer.than those of p.tients with one favor.ble p.ognostic factor.or.no favor.ble p.ognostic factor.(p.r.S mutation and p.EN p.otein exp.ession ar. significantly cor.

关键词： Cetuximab Metastatic color.ctal cancer Kr.S mutation p.osp.atase and tensin p.otein exp.ession

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The r.sults and p.ognosis of differ.nt tr.atment modalities for.solitar. metastatic lung tumor.fr.m nasop.ar.ngeal car.inoma:a r.tr.sp.ctive study of 105 cases

引用

Chinese Jour.al of cancer 2010年第9期29卷 787-795页

作者： Jun Ma1,2, Zhe-Sheng Wen1,2, p.ng Lin1,2, Xin Wang1,2, Fang-Yun Xie1,3 1 State Key Labor.tor. of oncology in South china, guangzhou, guangdong 510060, p.r.china 2 department of Thor.cic oncology, sun yat-sen university cancer center, guangzhou, guangdong 510060, p.r.china 3 department of r.diation oncology, sun yat-sen university cancer center, guangzhou, guangdong 510060, p.r.china department of Thor.cic Sur.er., Shanxi p.ovincial p.op.e’s Hosp.tal, Taiyuan, Shanxi 030012, p.r.china department of Thor.cic oncology Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China Guangdong Guangzhou 510060 department of r.diation oncology Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China Guangdong Guangzhou 510060

Backgr.und and Objective:Nasop.ar.ngeal car.inoma (Np.) is known for.its p.op.nsity for.distant *** metastasis is one of the most imp.r.ant causes of death for.p.tients with *** metastatic lung tumor.fr.m Np. is a distinctive gr.up.associated with a better.*** study was to find a mor. effective tr.atment modality and p.ognostic factor. for.the ***:Clinical data of 105 cases of solitar. metastatic lung tumor.fr.m Np. wer. r.tr.sp.ctively *** r.te was calculated by the Kap.an-Meier.*** differ.nce of sur.ival between the p.tients tr.ated by differ.nt modalities was evaluated by the log-r.nk *** Cox univar.ate and multivar.ate analyses of gender. age, p.thologic typ., stage, adjuvant chemother.p., evaluation of tr.atment for.Np., disease-fr.e inter.al, size of metastatic tumor. p.lmonar. hilar.and/or.mediastinal lymp. node metastasis, tr.atment modalities, r.cur.ent distant metastases and/or.r.lap.e of Np. wer. ***:The local contr.l r.te was 53.8% in chemother.p. gr.up. 88.0% in r.diother.p. +/-chemother.p. gr.up. and 96.4% in op.r.tion +/-chemother.p. gr.up.(p.0.01).The most p.omising p.ogr.ssion-fr.e sur.ival (p.S) and over.ll sur.ival (OS) wer. obtained with op.r.tion +/-chemother.p. and followed by r.diother.p. +/-*** of them showed much better.efficacy than chemother.p. (p.0.001).The Cox multivar.ate analysis showed that r.cur.ent distant metastases and/or.r.lap.e of Np. affected the sur.ival (Or.2.087, 95% CI=1.277-3.410, p.0.003).The T stage of Np., size of metastatic tumor. hilar.and/or.mediastinal lymp. node metastasis, and the tr.atment modality wer. indep.ndent p.ognostic ***:Op.r.tion +/-chemother.p. and r.diother.p. +/-chemother.p. ar. better.tr.atment of solitar. metastatic lung tumor.fr.m Np., which could imp.ove the local contr.l and p.olong the p.S and *** is r.commended for.p.tients with higher.T stage of Np., size of metastatic tu

关键词：治疗方式鼻咽癌预后孤立全国人民代表大会肺疗效评价多因素分析

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

A case r.p.r. of p.imar. small cell car.inoma of the br.ast and r.view of the liter.tur.

引用

Chinese Jour.al of cancer 2012年第7期31卷 354-358页

作者： Qi-Dong Ge1,2, Ning Lv1,2, Yun Cao1,3, Xi Wang1,2, Jun Tang1,2, Ze-Ming Xie1,2, Xiang-Sheng Xiao1,2, p.ng Liu1,2, Xiao-Ming Xie1,2 and Wei-Dong Wei1,2 Author.’ Affiliations: 1State Key Labor.tor. of oncology in South china, guangzhou, guangdong 510060, p. r. china 2department of Br.ast oncology, 3department of p.thology, sun yat-sen university cancer center, guangzhou, guangdong 510060, p. r. china. department of Br.ast oncology Sun Yat-sen University Cancer Center Guangzhou Guangdong People's Republic of China. weiweid@***

p.imar. small cell car.inoma (SCC) of the br.ast, an exceedingly r.r. and aggr.ssive tumor. is often char.cter.zed by r.p.d p.ogr.ssion and p.or.p.ognosis. We r.p.r. a case of p.imar. SCC of the br.ast that was diagnosed thr.ugh p.thologic and immunohistochemical examinations. Comp.ted tomogr.p.y (CT) scans failed to r.veal a non-mammar. p.imar. site. Due to the scant number.of r.levant case summar.es, this typ. of tumor.is p.oved to be a diagnostic and ther.p.utic challenge. Ther.for., we also r.viewed r.levant liter.tur. to shar. exp.r.ise in diagnosis, clinicop.thologic char.cter.stics, tr.atment, and p.ognosis of this typ. of tumor. Futur. studies with mor. cases ar. r.quir.d to define mor. ap.r.p.iate tr.atment indications for.this disease.

关键词：乳腺癌细胞文献计算机断层扫描原发性复习病理特征免疫组化

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Tr.atment outcomes for.differ.nt subgr.up. of nasop.ar.ngeal car.inoma p.tients tr.ated with intensity-modulated r.diation ther.p.

引用

Chinese Jour.al of cancer 2011年第8期30卷 565-573页

作者： Sheng-Fa Su 1,2,3,Fei Han 1,2,Chong Zhao 1,2,Ying Huang 1,2,Chun-Yan Chen 1,2,Wei-Wei Xiao 1,2,Jia-Xin Li 1,2 and Tai-Xiang Lu 1,2 1 State Key Labor.tor. of oncology in South china,guangzhou,guangdong 510060,p.r.china 2 department of r.diation oncology,sun yat-sen university cancer center,guangzhou,guangdong 510060,p.r.china 3 department of oncology,Guiyang medical College Hosp.tal,Tumor.Hosp.tal of Guizhou,Guiyang,Guizhou 550003,p.r.china. State Key Labor.tor. of oncology in South china Guangzhou Guangdong 510060 P. R. China.

Although many studies have investigated intensity-modulated r.diation ther.p. (IMr.) for.nasop.ar.ngeal car.inoma (Np.),samp.e sizes in the r.p.r.ed studies ar. usually small and differ.nt in outcomes in differ.nt T and N subgr.up. ar. seldom ***,we evaluated the outcomes of Np. p.tients tr.ated with IMr. and fur.her.exp.or.d tr.atment str.tegy to imp.ove such *** collected clinical data of 865 Np. p.tients tr.ated with IMr. alone or.in combination with chemother.p.,and classified all cases into the following p.ognostic categor.es accor.ing to differ.nt TNM stages:ear.y stage gr.up.(T1-2N0-1M0),advanced local disease gr.up.(T3-4N0-1M0),advanced nodal disease gr.up.(T1-2N2-3M0),and advanced locor.gional disease gr.up.(T3-4N2-3M0).The 5-year.over.ll sur.ival (OS),local r.lap.e-fr.e sur.ival (Lr.S),and distant metastases-fr.e sur.ival (DMFS) wer. 83.0%,90.4%,and 84.0%,*** ear.y disease gr.up.had the lowest tr.atment failur. r.te,with a 5-year.OS of 95.6%.The advanced local disease gr.up.and advanced nodal disease gr.up.had similar.failur. p.tter. and tr.atment outcomes as well as similar.hazar. r.tios for.death (4.230 and 4.625,r.sp.ctively).The advanced locor.gional disease gr.up.had the highest incidence of r.lap.e and death,with a 5-year.DMFS and OS of 62.3% and 62.2%,r.sp.ctively,and a hazar. r.tio for.death of *** with IMr. alone,IMr. in combination with chemother.p. p.ovided no significant benefit to locor.gionally advanced *** r.sults suggest that the decision of tr.atment str.tegy for.Np. p.tients should consider.combinations of T and N stages,and that IMr. alone for.ear.y stage Np. p.tients can p.oduce satisfactor. ***,for.advanced local,nodal,and locor.gional disease gr.up.,a combination of chemother.p. and r.diother.p. is r.commended.

关键词：放射治疗强度调制鼻咽癌患者调控样本大小临床资料结合治疗

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

p.ognosis of 980 p.tients with gastr.c cancer after.sur.ical r.section

引用

Chinese Jour.al of cancer 2010年第11期29卷 923-930页

作者： Wei Wang1,2, Yuan-Fang Li1,2, Xiao-Wei sun1,2, Ying-Bo Chen1,2, Wei Li1,2, Da-Zhi Xu1,2, Xuan-Xiang Guan1,2, Chun-Yu Huang1,2, You-Qing Zhan1,2, Zhi-Wei Zhou1,2 1 State Key Labor.tor. of oncology in South china, guangzhou, guangdong 510060, p. r. china 2 department of Gastr.c and p.ncr.atic Sur.er., sun yat-sen university cancer center, guangzhou, guangdong 510060, p. r. china department of Gastr.c and p.ncr.atic Sur.er. Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China Guangdong Guangzhou 510060

Backgr.und and Objective: Although sur.er. is the only p.ssible means to cur. gastr.c cancer, the p.ognosis is often discr.p.nt. The Amer.can Joint Committee on cancer/Inter.ational Union against cancer (AJCC/UICC) p.blished the TNM classification of Malignant Tumor. (seventh edition) for.gastr.c cancer r.cently. This study aimed to use this new edition staging system to investigate the p.ognostic factor. for.gastr.c cancer. Methods: The clinicop.thologic data of 980 p.tients with gastr.c cancer tr.ated by sur.ical r.section in our.hosp.tal between Januar. 2000 and December.2006 wer. analyzed r.tr.sp.ctively. The over.ll sur.ival r.te was deter.ined by using Kap.an-Meier.method and log-r.nk test was used to deter.ine significance. The p.ognosis was analyzed using univar.ate analysis and multivar.ate analysis with the Cox p.op.r.ional hazar.s model. The 6th and 7th edition AJCC/UICC TNM staging systems wer. used to comp.r. the sur.ival outcomes for.the cohor. of p.tients. r.sults: The over.ll 1-, 3-, 5-year.sur.ival r.tes for.the whole gr.up.wer. 82.5%, 58.7%, and 52.6%. The 5-year.sur.ival r.tes for.p.tients with p.NM stage I, II, III, and IV disease classified by the 7th edition staging system wer. 93.2%, 72.4%, 39.1%, and 5.2%, r.sp.ctively. In both univar.ate analysis and Cox multivar.ate analysis, age, tumor.site, tumor.size, histological typ., r.section typ., r.dical r.section, lymp.atic/venous invasion, dep.h of invasion, nodal status, metastasis, r.tr.eved lymp. nodes, metastatic lymp. node r.tio, and adjuvant chemother.p. wer. p.ognostic factor. with these p.tients. Conclusion: Comp.r.d with the 6th edition system, the new edition of TNM staging system for.gastr.c cancer can accur.tely p.edict the sur.ival after.op.r.tion.

关键词：手术切除胃癌预后多因素分析单因素分析恶性肿瘤 TNM 淋巴结

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：